We then assessed the 36 serrated morphology human CRC cases, finding that 30 (83.3%) had strong PDX1 expression, including all 26 of the cases with CDX2 loss/reduction and/or BRAFT1799A mutations (Figure 1 and Figure 6B). The gene discussed is CDX2; the disease is colorectal carcinoma.